Close Menu

cervical cancer

This story has been updated from a previous version to clarify comments regarding the Aptima HPV test specificity.
By Ben Butkus

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

The assay may provide insight into the relationships between various HPV types and their associated diseases — not just cervical cancer, but also potentially head and neck cancers and HPV-associated warts.

Roche presents data from HPV Dx trial; Epigenomics launches Epi proLung BL Reflex Assay in Europe.

Incell's HPV test will be run on Accuri's cytometer as a cervical cancer screening tool.

Enzo Clinical Labs will market the cervical cancer test in New York and New Jersey.

Using gene dosage, expression, and ontology data, the researchers identified recurrent changes linked to cervical cancer development and treatment outcomes.

After comparing results from Qiagen's HPV DNA test with cytology-based screening in more than 100,000 women, the researchers concluded that the HPV test is more sensitive, though its specificity varied by age group.


NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.